Slow coronary flow phenomenon (SCFP) is characterized by angiographically normal coronary arteries with delayed run-off of contrast medium across the vasculature. Its etiology and clinical significance are still not completely known; however, acute congestive heart failure (CHF) is rare in this context. A 71 year-old woman with SCFP presented with acute CHF complicated by ventricular tachycardia. Treated with rosuvastatin (20 mg/day for 6 days) and inotropic drug infusion she had a complete recovery of left ventricular function and normalization of serum levels of the high-sensitivity C-reactive protein (hs-CRP), which were increased (3.6 mg/L) during the acute phase. This case illustrates that the anti-inflammatory properties of rosuvastatin may deserve specific clinical tests not only during the chronic phase but also in the acute phase of CHF patients. © Arrivi et al.
Rosuvastatin was effective in acute heart failure and slow coronary flow: A hypothesis-generating case report / Alessio, Arrivi; Tanzilli, Gaetano; Puddu, Paolo Emilio; L., Iannucci; Mangieri, Enrico. - In: THE OPEN CARDIOVASCULAR MEDICINE JOURNAL. - ISSN 1874-1924. - STAMPA. - 7:1(2013), pp. 12-15. [10.2174/1874192401307010012]
Rosuvastatin was effective in acute heart failure and slow coronary flow: A hypothesis-generating case report
TANZILLI, Gaetano;PUDDU, Paolo Emilio;MANGIERI, Enrico
2013
Abstract
Slow coronary flow phenomenon (SCFP) is characterized by angiographically normal coronary arteries with delayed run-off of contrast medium across the vasculature. Its etiology and clinical significance are still not completely known; however, acute congestive heart failure (CHF) is rare in this context. A 71 year-old woman with SCFP presented with acute CHF complicated by ventricular tachycardia. Treated with rosuvastatin (20 mg/day for 6 days) and inotropic drug infusion she had a complete recovery of left ventricular function and normalization of serum levels of the high-sensitivity C-reactive protein (hs-CRP), which were increased (3.6 mg/L) during the acute phase. This case illustrates that the anti-inflammatory properties of rosuvastatin may deserve specific clinical tests not only during the chronic phase but also in the acute phase of CHF patients. © Arrivi et al.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.